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Abstract	  
	  Biliary	  Atresia	  (BA)	  is	  characterized	  by	  a	  progressive	  obliteration	  of	  all,	  or	  part	  of,	  the	  extrahepatic	  biliary	  tree1,5.	  It	  is	  the	  primary	  indication	  for	  pediatric	  liver	  transplantation,	  responsible	  for	  approximately	  50%	  of	  all	  pediatric	  liver	  transplants1-­‐6.	  The	  resting	  energy	  expenditure	  of	  children	  living	  with	  BA	  is	  30-­‐50%	  higher	  than	  that	  of	  healthy	  children	  of	  the	  same	  age	  because	  children	  with	  BA	  must	  consume	  additional	  calories	  to	  promote	  liver	  regeneration6,9,10.	  	  BA	  prevents	  bile	  from	  traveling	  from	  the	  liver	  into	  the	  intestine,	  where	  it	  is	  crucial	  for	  fat	  absorption.	  Bile	  insufficiency	  in	  the	  intestine	  results	  in	  malnutrition,	  malabsorption,	  and	  fat-­‐soluble	  vitamin	  (ADEK)	  deficiencies.	  Sixty	  to	  80%	  of	  children	  with	  end-­‐stage	  liver	  disease	  exhibit	  moderate	  to	  severe	  malnutrition	  before	  liver	  transplantation12.	  By	  examining	  a	  child	  living	  with	  BA	  hospitalized	  at	  UNC-­‐Hospitals,	  I	  explored	  the	  medical	  nutrition	  therapy	  for	  patients	  with	  BA	  before	  liver	  transplantation.	  According	  to	  the	  most	  recent	  research,	  the	  best	  nutritional	  treatment	  for	  BA	  patients	  before	  liver	  transplantation	  includes	  cycled	  EN	  nocturnal	  feeding	  with	  daily	  oral	  feeds	  using	  formula	  with	  a	  high	  MCT:LCT	  ratio10,19.	  To	  prevent	  deficiencies,	  it	  is	  strongly	  recommended	  that	  BA	  patients	  be	  provided	  with	  130-­‐150%	  of	  the	  caloric	  DRI	  for	  age,	  2.5-­‐3	  g/kg/d	  of	  protein,	  and	  ADEK	  supplements10,11,32.	  	  	  
Introduction	   	  	  Biliary	  Atresia	  (BA)	  occurs	  world	  wide,	  affecting	  approximately	  1	  in	  8,000	  to	  1	  in	  18,000	  of	  live	  births1-­‐4.	  BA	  is	  characterized	  by	  a	  progressive	  obliteration	  of	  all,	  or	  part	  of,	  the	  extrahepatic	  biliary	  tree1,5.	  When	  the	  extrahepatic	  biliary	  tree	  is	  damaged,	  bile	  is	  unable	  to	  travel	  from	  the	  liver	  into	  the	  intestine,	  causing	  bile	  entrapment	  in	  the	  liver	  leading	  to	  cirrhosis,	  and	  resulting	  in	  malabsorption	  of	  fats	  in	  the	  intestine.	  BA	  presents	  within	  the	  first	  three	  months	  of	  life	  and	  is	  the	  most	  common	  indication	  for	  pediatric	  liver	  transplantation,	  responsible	  for	  approximately	  50%	  of	  all	  pediatric	  liver	  transplants1-­‐6.	  If	  a	  BA	  patient	  goes	  completely	  untreated,	  the	  liver	  will	  become	  cirrhotic	  and	  the	  child	  will	  die	  within	  18-­‐24	  months	  of	  life5.	  	  BA	  is	  a	  clinical	  phenotype,	  likely	  resulting	  from	  multiple	  prenatal	  and	  perinatal	  insults	  to	  the	  hepatobiliary	  tree4.	  There	  are	  at	  least	  four	  phenotypes	  of	  BA,	  however	  the	  etiology	  and	  pathogenesis	  of	  each	  type	  remains	  unknown1,4.	  The	  two	  major	  forms	  of	  BA	  are	  understood	  as:	  1)	  The	  embryonic	  form,	  which	  is	  associated	  with	  other	  congenital	  anomalies	  and	  involves	  abdominal	  situs,	  such	  as	  polysplenia	  and	  intestinal	  malrotation,	  and	  2)	  The	  
perinatal	  form,	  in	  which	  the	  infant	  is	  initially	  considered	  healthy,	  but	  postnatal	  events	  that	  occur	  within	  the	  first	  three	  months	  of	  life	  trigger	  progressive	  inflammation	  and	  fibro-­‐obliteration	  of	  the	  normally	  developed	  biliary	  tree2-­‐4,7.	  The	  perinatal	  form	  is	  most	  common,	  affecting	  80%	  of	  BA	  cases3,4.	  	  	  BA	  patients	  typically	  present	  with	  hyperbilirubinemia,	  jaundice,	  hepatomegaly,	  dark	  urine,	  diarrhea,	  and/or	  fatty,	  pale,	  acholic	  stools4,8,9.	  When	  an	  infant	  presents	  with	  these	  clinical	  
symptoms,	  a	  hepatobiliary	  iminodiacetic	  scan	  is	  performed	  to	  observe	  how	  bile	  flows	  from	  the	  liver.	  If	  the	  scan	  shows	  minimal	  bile	  leaving	  the	  liver,	  an	  exploratory	  laparotomy	  is	  performed	  in	  order	  to	  confirm	  BA.	  	  	  The	  primary	  treatment,	  other	  than	  liver	  transplantation,	  is	  the	  Kasai	  procedure,	  which	  has	  most	  success	  when	  performed	  as	  early	  as	  possible,	  before	  three	  months	  of	  age1,2.	  During	  this	  procedure,	  the	  surgeon	  removes	  damaged	  bile	  ducts	  and	  attaches	  a	  loop	  of	  the	  small	  intestine	  to	  smaller	  ducts	  that	  are	  still	  draining	  bile.	  This	  enables	  bile	  to	  flow	  directly	  from	  the	  liver	  into	  the	  intestine35.	  A	  successful	  Kasai	  procedure	  is	  designed	  to	  prevent	  cirrhosis	  development	  and	  fat	  malabsorption1.	  	  However,	  due	  to	  progressive	  inflammation	  and	  fibrosis	  of	  intrahepatic	  bile	  ducts,	  70%	  of	  patients	  with	  seemingly	  successful	  Kasai	  procedures	  eventually	  develop	  cirrhosis	  and	  require	  liver	  transplantation	  within	  the	  first	  two	  years	  of	  life2-­‐4.	  	  	  When	  jaundice	  resolves	  within	  three	  months	  after	  the	  Kasai	  procedure,	  the	  10-­‐year	  transplant-­‐free	  survival	  rate	  is	  75-­‐90%1.	  However,	  if	  jaundice	  continues	  for	  three	  months	  after	  the	  procedure,	  the	  three-­‐year	  transplant-­‐free	  survival	  rate	  is	  approximately	  20%1.	  Failed	  Kasai	  procedures	  are	  common	  and	  often	  lead	  to	  death	  if	  the	  infant	  does	  not	  receive	  a	  liver	  transplant11.	  Infants	  who	  have	  undergone	  a	  failed	  Kasai	  procedure	  have	  not	  survived	  beyond	  24-­‐36	  months	  without	  receiving	  a	  liver	  transplant1,6.	  Recent	  studies	  show	  that	  long-­‐term	  survival	  without	  a	  transplant	  can	  be	  better	  achieved	  in	  BA	  patients	  if	  the	  Kasai	  procedure	  is	  performed	  within	  the	  first	  30-­‐45	  days	  of	  life2.	  However,	  there	  are	  no	  convenient	  methods	  to	  screen	  newborns	  for	  BA,	  so	  diagnosis	  within	  the	  first	  two	  to	  three	  months	  of	  life	  is	  uncommon2.	  	  The	  resting	  energy	  expenditure	  of	  children	  living	  with	  BA	  is	  30-­‐50%	  higher	  than	  that	  of	  healthy	  children	  of	  the	  same	  age	  because	  children	  with	  BA	  must	  consume	  additional	  calories	  to	  promote	  liver	  regeneration6,9,10.	  	  BA	  prevents	  bile	  from	  traveling	  from	  the	  liver	  into	  the	  intestine,	  where	  it	  is	  crucial	  for	  fat	  absorption.	  Bile	  insufficiency	  in	  the	  intestine	  results	  in	  malnutrition,	  malabsorption,	  and	  fat-­‐soluble	  vitamin	  (ADEK)	  deficiencies.	  Sixty	  to	  80%	  of	  children	  with	  end-­‐stage	  liver	  disease	  exhibit	  moderate	  to	  severe	  malnutrition	  before	  liver	  transplantation12.	  Malnutrition	  continues	  during	  the	  first	  year	  of	  life	  because	  BA	  patients	  require	  time	  to	  replenish	  what	  was	  lost	  before	  the	  Kasai	  procedure	  and/or	  liver	  transplantation5.	  BA	  patients	  must	  replenish	  fat	  reserves,	  muscles,	  structural	  proteins,	  and	  bone	  mineralization5.	  	  	  Forty	  percent	  of	  infants	  who	  underwent	  liver	  transplantation	  have	  growth	  failure	  and	  developmental	  delay	  before	  transplantation	  because	  of	  loss	  of	  muscle	  mass	  and	  structural	  proteins,	  impaired	  bone	  mineralization,	  and	  depleted	  fat	  reserves1,5,6.	  Because	  of	  intestinal	  bile	  insufficiency,	  BA	  patients	  also	  develop	  biochemical	  and	  clinical	  deficiencies	  of	  ADEK	  vitamins,	  which	  may	  cause	  complications	  such	  as	  metabolic	  bone	  disease,	  hemorrhaging,	  and	  anemia1,11.	  	  Stunting	  remains	  common	  in	  infants	  with	  BA,	  despite	  nutrition-­‐modified	  formulas	  adjusted	  to	  properly	  nourish	  infants	  who	  are	  deficient	  in	  bile	  acids.	  Exclusive	  oral	  intake	  may	  not	  be	  effective	  for	  appropriate	  growth	  in	  infants	  living	  with	  BA,	  and	  therefore	  enteral	  nutrition	  (EN)	  and	  vitamin	  supplementation	  may	  be	  required	  in	  order	  for	  these	  patients	  to	  receive	  adequate	  nutrition5.	  	  
	  By	  examining	  a	  child	  living	  with	  BA	  hospitalized	  at	  UNC-­‐Hospitals,	  I	  will	  explore	  the	  medical	  nutrition	  therapy	  for	  patients	  with	  BA	  before	  liver	  transplantation.	  	  
Case	  study	  	  An	  African-­‐American	  female	  had	  an	  uncomplicated	  gestation	  and	  delivery	  in	  2015.	  The	  child’s	  primary	  nutrition	  source	  during	  her	  first	  two	  months	  of	  life	  was	  Gerber	  Soy	  20	  kcal/oz.	  She	  was	  fed	  a	  soy-­‐based	  formula	  because	  she	  had	  discomfort,	  gas,	  and	  excessive	  stools	  when	  ingesting	  lactose-­‐based	  formulas.	  The	  child	  consumed	  4	  oz.	  every	  three	  hours,	  for	  a	  total	  of	  eight	  feeds/day,	  totaling	  147	  kcal/kg/day	  (123%	  of	  the	  DRI).	  The	  child	  was	  also	  given	  a	  vitamin	  D3	  supplement.	  	  The	  child’s	  total	  and	  direct	  bilirubin	  levels	  were	  elevated	  the	  first	  and	  second	  day	  after	  birth.	  Her	  hyperbilirubinemia	  was	  likely	  caused	  by	  reduced	  secretions	  of	  bilirubin	  into	  the	  bile,	  which	  commonly	  occurs	  in	  patients	  with	  biliary	  obstruction13.	  The	  bilirubin	  lab	  results	  were	  her	  first	  clinical	  symptoms	  of	  BA.	  However,	  she	  was	  not	  diagnosed	  with	  BA	  until	  about	  two	  months	  later.	  	  A	  primary	  care	  physician	  saw	  the	  child	  about	  one	  month	  after	  birth	  for	  complaints	  of	  fussiness,	  gas,	  and	  difficulty	  passing	  stools.	  The	  child	  was	  passing	  four	  white,	  large	  stools	  each	  day.	  Her	  total	  bilirubin,	  direct	  bilirubin,	  and	  indirect	  bilirubin	  levels	  (6.74,	  3.90,	  2.80,	  respectively)	  were	  elevated	  and	  the	  primary	  care	  physician	  noted	  that	  the	  child	  appeared	  jaundiced.	  The	  primary	  care	  physician	  referred	  the	  patient	  to	  a	  pediatric	  gastroenterologist,	  who	  saw	  the	  child	  one	  week	  later.	  The	  pediatric	  gastroenterologist	  ordered	  a	  hepatobiliary	  iminodiacetic	  scan	  which	  showed	  a	  lack	  of	  biliary	  excretion.	  A	  pediatric	  surgeon	  performed	  an	  exploratory	  laparotomy	  when	  the	  child	  was	  two	  months	  old.	  BA	  was	  confirmed	  during	  surgery,	  and	  the	  Kasai	  procedure	  was	  performed	  without	  complication.	  However,	  a	  CT	  scan	  three	  months	  after	  surgery	  showed	  that	  the	  Kasai	  procedure	  had	  failed.	  	  	  After	  the	  Kasai	  procedure,	  the	  patient	  experienced	  multiple	  complications,	  such	  as	  jaundice,	  ascending	  cholangitis,	  suspected	  varices,	  and	  gastrointestinal	  (GI)	  bleeding.	  At	  17	  months	  of	  age,	  she	  was	  hospitalized	  because	  of	  GI	  bleeding	  and	  was	  diagnosed	  with	  systemic	  inflammatory	  response	  syndrome	  and	  severe	  anemia.	  During	  this	  hospital	  stay,	  she	  experienced	  hypovolemic	  shock.	  GI	  bleeding	  has	  continued	  and	  the	  medical	  team	  has	  been	  unable	  to	  find	  the	  source	  of	  the	  bleed.	  	  Nutrition	  Interventions:	  	  After	  the	  Kasai	  procedure	  at	  two	  months	  old,	  the	  child	  was	  not	  given	  food	  orally	  until	  her	  bowel	  function	  returned.	  Her	  diet	  was	  advanced	  to	  Pregestimil	  20	  kcal/oz,	  a	  formula	  provided	  to	  patients	  who	  have	  difficulty	  absorbing	  fats14.	  However	  she	  refused	  the	  Pregestimil.	  It	  is	  likely	  the	  child	  is	  lactose	  intolerant	  because	  she	  presented	  with	  gas	  and	  discomfort	  after	  consumption	  of	  lactose-­‐based	  formulas,	  such	  as	  Pregestimil.	  So,	  she	  was	  instead	  fed	  Prosobee,	  a	  soy-­‐based	  formula	  primarily	  used	  to	  decrease	  fussiness	  and	  gas15.	  She	  also	  received	  an	  ADEK	  supplement.	  	  	  
She	  was	  discharged	  five	  days	  after	  surgery	  and	  consumed	  Gerber	  Soy	  formula	  and	  Prosobee	  formula	  at	  home.	  Gerber	  Soy	  and	  Prosobee	  are	  formulas	  made	  by	  different	  companies,	  however	  are	  both	  soy-­‐based,	  lactose-­‐free	  formulas	  that	  contain	  similar	  proportions	  of	  macro-­‐	  and	  micronutrients15,16.	  ADEK	  supplementation	  continued.	  	  	  At	  six	  months	  old,	  the	  child	  began	  to	  eat	  baby	  foods	  while	  also	  consuming	  Prosobee.	  During	  more	  recent	  hospital	  stays,	  at	  age	  15-­‐17	  months,	  the	  child	  has	  been	  eating	  baby	  foods	  while	  drinking	  Pediasure	  Peptide	  mixed	  with	  soymilk.	  Pediasure	  Peptide	  is	  a	  peptide-­‐based	  formula	  that	  is	  easier	  for	  children	  with	  malabsorption,	  maldigestion,	  and	  other	  GI	  conditions	  to	  digest17.	  Despite	  taking	  ADEK	  supplements	  throughout	  her	  life,	  at	  17	  months	  old,	  her	  vitamin	  D	  level	  was	  less	  than	  5ng/mL,	  showing	  that	  she	  was	  not	  absorbing	  ADEK	  vitamins.	  	  Patient	  Growth:	  Despite	  risks	  for	  malnutrition	  and	  growth	  failure,	  the	  child	  has	  continued	  to	  gain	  weight	  appropriately,	  currently	  following	  the	  85th	  percentile	  for	  age	  (Figure	  1).	  Although	  she	  experienced	  some	  episodes	  of	  weight	  loss	  because	  of	  vomiting	  and	  GI	  bleeding,	  her	  overall	  growth	  has	  been	  appropriate	  in	  length	  and	  weight	  for	  her	  age.	  	  
	  
Figure	  1:	  Weight-­‐for-­‐length	  Percentiles	  (Girls,	  birth	  to	  2	  years)	  	  
	  
	  Figure	  1	  shows	  the	  child’s	  growth	  on	  a	  weight-­‐for-­‐length	  percentile	  graph	  of	  girls	  from	  birth	  to	  two	  years	  of	  age,	  highlighting	  the	  time	  of	  diagnosis,	  Kasai	  procedure,	  medical	  complications,	  and	  nutrition	  interventions.	  	  
	  Figure	  1	  shows	  the	  child’s	  increased	  rate	  of	  growth	  after	  the	  Kasai	  procedure.	  During	  the	  time	  the	  child	  was	  experiencing	  GI	  bleeding,	  the	  rate	  of	  growth	  decreased,	  but	  the	  patient’s	  overall	  weight-­‐for-­‐length	  has	  steadily	  and	  appropriately	  increased,	  parallel	  to	  the	  50th-­‐85th	  percentiles	  for	  age.	  	  	  Since	  the	  child’s	  weight	  may	  be	  misinterpreted	  due	  to	  hepatomegaly	  and	  fluid	  retention,	  it	  is	  crucial	  to	  also	  examine	  her	  length	  independently	  of	  her	  weight	  in	  order	  to	  fully	  understand	  her	  growth.	  Figure	  2	  shows	  the	  child’s	  length-­‐for-­‐age	  when	  compared	  to	  her	  age	  group.	  	  
Figure	  2:	  Length-­‐for-­‐age	  Percentiles	  (Girls,	  birth	  to	  2	  years)	  	  
	  Figure	  2	  shows	  the	  child’s	  growth	  on	  a	  length-­‐for-­‐age	  percentile	  graph	  of	  girls	  from	  birth	  to	  two	  years	  of	  age,	  highlighting	  the	  time	  of	  diagnosis,	  Kasai	  procedure,	  medical	  complications,	  and	  nutrition	  interventions.	  	  	  The	  child’s	  length	  increased	  from	  the	  15th	  to	  50th	  percentile	  for	  age	  after	  the	  Kasai	  procedure,	  between	  2-­‐8.5	  months	  of	  age	  (Figure	  2).	  Her	  length	  has	  remained	  between	  the	  15th	  and	  50th	  percentiles	  while	  consuming	  baby	  foods	  with	  Prosobee	  and	  baby	  foods	  with	  supplemental	  Pediasure	  Peptide.	  During	  the	  time	  of	  the	  child’s	  GI	  bleeding,	  length	  decreased	  to	  the	  3rd	  percentile	  for	  age.	  	  However,	  overall	  the	  child’s	  length-­‐for-­‐age	  has	  appropriately	  increased.	  Appropriate	  weight-­‐for	  length	  and	  length-­‐for-­‐age	  illustrates	  that	  the	  child	  has	  shown	  appropriate	  overall	  growth.	  
	  Transplant	  Approval:	  The	  Pediatric	  End-­‐stage	  Liver	  Disease	  (PELD)	  is	  the	  scoring	  system	  used	  by	  the	  Universal	  Network	  for	  Organ	  Sharing	  for	  patients	  who	  are	  eleven	  years	  old	  or	  younger18.	  It	  ranks	  patients	  on	  the	  liver	  transplant	  waitlist	  by	  measuring	  bilirubin	  (a	  measurement	  of	  how	  well	  the	  liver	  excretes	  bile),	  albumin	  (a	  measurement	  of	  how	  well	  the	  liver	  maintains	  nutrition),	  prothrombin	  time	  (a	  measurement	  of	  the	  liver’s	  ability	  to	  make	  blood	  clotting	  factors),	  growth	  failure,	  and	  whether	  the	  child	  is	  less	  than	  one-­‐year	  old18.	  	  	  The	  child	  was	  approved	  for	  the	  pediatric	  liver	  transplant	  waitlist	  at	  17	  months	  old	  when	  her	  lab	  values	  showed	  an	  elevated	  total	  bilirubin	  of	  4.6,	  a	  low	  albumin	  of	  2.8,	  and	  an	  elevated	  prothrombin	  time	  of	  1.16,	  giving	  an	  initial	  PELD	  score	  of	  4.	  To	  offer	  a	  comparison,	  a	  PELD	  score	  of	  15	  is	  the	  median	  score	  of	  a	  child	  at	  the	  time	  of	  a	  pediatric	  liver	  transplantation1.	  	  
	  
Discussion	  
	  Pros	  and	  Cons	  of	  Liver	  Transplantation:	  Liver	  transplantation	  has	  many	  risks,	  including	  intestinal	  perforation,	  hepatic	  arterial	  thrombosis,	  and	  bile	  duct	  strictures6.	  Forty-­‐eight	  percent	  of	  children	  require	  additional	  operations	  for	  biliary	  strictures	  after	  receiving	  a	  new	  liver6.	  Although	  liver	  transplantation	  has	  multiple	  risks,	  there	  are	  many	  benefits.	  For	  instance,	  there	  is	  an	  excellent	  10-­‐year	  post	  liver	  transplantation	  survival	  rate1.	  Furthermore,	  after	  a	  failed	  Kasai	  procedure,	  mortality	  rates	  are	  high	  for	  patients	  who	  do	  not	  undergo	  a	  liver	  transplantation1,6.	  	  	  Medical	  Nutrition	  Therapy	  for	  BA	  Patients	  Before	  Transplant:	  Protein-­‐energy	  malnutrition	  is	  a	  common	  complication	  in	  BA	  patients	  before	  surgery,	  and	  may	  persist	  after	  surgery19.	  Effective	  medical	  nutrition	  therapy	  is	  crucial	  for	  BA	  patients	  before	  liver	  transplantation	  because	  adequate	  nutrition	  optimizes	  results	  post-­‐operatively10.	  Because	  of	  the	  lack	  of	  bile	  in	  the	  intestine,	  BA	  patients	  are	  at	  high	  risk	  for	  failure	  to	  thrive,	  malabsorption,	  and	  ADEK	  deficiencies.	  Growth	  failure	  before	  transplant	  predicts	  post-­‐transplant	  death6.	  Therefore,	  it	  is	  imperative	  that	  BA	  patients	  receive	  the	  proper	  amounts	  of	  macro-­‐	  and	  micronutrients.	  Children	  with	  BA	  require	  130-­‐150%	  of	  the	  caloric	  DRI	  for	  age,	  2.5-­‐3	  g/kg/d	  of	  protein,	  and	  ADEK	  supplementation10.	  Increased	  calories	  are	  required	  to	  promote	  liver	  regeneration10.	  Increased	  protein	  consumption	  is	  necessary	  to	  blunt	  the	  catabolic	  state	  that	  is	  common	  in	  a	  BA	  patient	  while	  improving	  the	  patient’s	  growth	  rate10.	  In	  children,	  it	  is	  rarely	  necessary	  to	  decrease	  protein	  consumption	  because	  of	  hepatic	  encephalopathy10.	  ADEK	  supplementation	  is	  necessary	  to	  prevent	  any	  ADEK	  deficiencies	  caused	  by	  the	  fat	  malabsorption	  that	  occurs	  in	  this	  population.	  	  Although	  exclusive	  breastfeeding	  during	  the	  first	  six	  months	  of	  life	  is	  recommended	  for	  healthy	  infants,	  those	  with	  BA	  may	  not	  benefit	  because	  of	  their	  increased	  needs	  for	  macro-­‐	  and	  micronutrients.	  Studies	  show	  that	  exclusive	  breastfeeding	  of	  BA	  patients	  results	  in	  decreased	  growth	  because	  breast	  milk	  does	  not	  provide	  enough	  calories	  and	  protein	  for	  this	  population11.	  Patients	  with	  BA	  have	  elevated	  estimated	  needs	  when	  compared	  to	  the	  average	  infant	  of	  a	  similar	  age	  because	  of	  liver	  degeneration.	  Providing	  supplemental	  
feeding	  immediately	  after	  the	  Kasai	  procedure	  results	  in	  better	  nutrition	  outcomes	  than	  interventions	  at	  a	  later	  age	  or	  only	  immediately	  before	  transplant12.	  Those	  with	  BA	  require	  daily	  supplementation	  with	  formula.	  	  Additionally,	  because	  breast	  milk	  does	  not	  supply	  enough	  vitamin	  K	  for	  the	  average	  infant,	  it	  is	  recommended	  that	  all	  newborns	  receive	  vitamin	  K	  supplements20.	  Since	  BA	  patients	  are	  more	  prone	  to	  ADEK	  malabsorption	  and	  deficiency,	  it	  is	  even	  more	  crucial	  that	  BA	  patients	  receive	  vitamin	  K	  supplements	  to	  avoid	  vitamin	  K-­‐deficiency-­‐related	  bleeding	  and	  death20.	  	  	  
MCT	  Formulas:	  BA	  patients	  have	  defective	  fat	  digestion	  and	  absorption	  because	  of	  intestinal	  bile	  insufficiency11.	  Bile	  aids	  in	  fat	  absorption	  by	  forming	  a	  micelle	  with	  the	  products	  of	  triacylglycerol	  digestion:	  fatty	  acids	  and	  monoacylglycerol21.	  The	  formation	  of	  micelles	  allows	  these	  products	  of	  fatty	  acid	  digestion	  to	  cross	  the	  brush	  border	  and	  enter	  the	  mucosal	  cells	  of	  the	  small	  intestine.	  Once	  in	  the	  mucosal	  cells,	  fatty	  acids	  and	  monoacylglycerol	  are	  reassembled	  into	  triglycerides,	  and	  then	  secreted	  into	  the	  lymphatic	  system	  as	  chylomicra21.	  Deficiency	  of	  intestinal	  bile	  causes	  defective	  digestion	  and	  absorption	  of	  fats	  because	  fatty	  acids	  and	  monoacylglycerol	  are	  then	  unable	  to	  form	  with	  bile	  and	  other	  byproducts	  to	  produce	  a	  micelle	  and	  enter	  the	  mucosal	  cells	  of	  the	  small	  intestine11.	  However,	  fats	  varying	  in	  fatty	  acid	  chain	  length	  are	  absorbed	  differently22.	  For	  instance,	  the	  absorption	  of	  medium-­‐chain	  triglycerides	  (MCTs),	  which	  contain	  six	  to	  twelve	  carbon	  fatty	  acids,	  differs	  from	  the	  absorption	  of	  long-­‐chain	  triglycerides	  (LCTs),	  which	  contain	  fatty	  acids	  longer	  than	  twelve	  carbons22.	  Medium	  chain	  fatty	  acids	  are	  absorbed	  directly	  into	  the	  portal	  blood	  and	  are	  then	  transferred	  directly	  to	  the	  liver	  for	  oxidation,	  whereas	  the	  fatty	  acids	  of	  LCTs	  require	  bile	  to	  enter	  mucosal	  cells	  of	  the	  small	  intestine	  in	  order	  to	  be	  absorbed	  properly	  and	  be	  secreted	  as	  chylomicra	  into	  the	  lymph22.	  	  	  Dietitians	  provide	  formulas	  with	  increased	  MCT:LCT	  ratios	  to	  patients	  with	  fat	  malabsorption	  because	  the	  fatty	  acids	  from	  MCTs	  are	  more	  readily	  absorbed	  than	  those	  from	  LCTs23,24.	  MCTs	  are	  better	  absorbed	  in	  patients	  with	  cholestasis,	  a	  group	  of	  conditions	  in	  which	  the	  flow	  of	  bile	  from	  the	  liver	  is	  defective4,10.	  	  	  When	  infant	  formula,	  which	  provides	  fat	  as	  LCTs,	  was	  compared	  to	  a	  formula	  containing	  40%	  of	  its	  fat	  from	  MCTs,	  the	  MCT-­‐fed	  infants’	  stools	  showed	  a	  higher	  percent	  absorption	  of	  fat	  compared	  to	  the	  LCT-­‐fed	  infants	  (95.2%	  vs.	  89.9%)23.	  In	  a	  separate	  study,	  premature	  infants	  were	  fed	  two	  isocaloric	  formulas	  containing	  either	  MCTs	  or	  LCTs	  for	  fifteen	  days;	  the	  alternate	  formula	  was	  given	  for	  a	  second	  period	  of	  fifteen	  days25.	  While	  consuming	  the	  MCT	  formula,	  infants	  showed	  greater	  fat	  absorption	  (97.1%	  vs.	  83.4%)	  and	  better	  weight	  gain	  (11.5	  g/kg/100kcal	  vs.	  7.5	  g/kg/100kcal)	  than	  when	  consuming	  the	  LCT	  formula25.	  	  However,	  we	  must	  not	  decrease	  LCTs	  to	  less	  than	  10%	  of	  the	  total	  fat	  content	  in	  the	  formula	  in	  order	  to	  prevent	  essential	  fatty	  acid	  deficiencies10.	  	  Pregestimil	  was	  the	  first	  formula	  offered	  to	  the	  case	  study	  patient	  after	  her	  Kasai	  procedure	  because	  it	  provides	  a	  high	  amount	  of	  calories,	  24	  kcal/oz,	  while	  promoting	  fat	  absorption	  with	  an	  elevated	  MCT:LCT	  ratio	  of	  55:4514.	  Pregestimil	  is	  commonly	  used	  for	  
children	  who	  malabsorb	  fat	  because	  standard	  pediatric	  formulas	  only	  have	  an	  MCT:LCT	  ratio	  of	  15:8526.	  The	  increased	  MCT:LCT	  ratio	  in	  Pregestimil	  allows	  BA	  patients	  to	  better	  absorb	  fats.	  Pregestimil	  is	  offered	  in	  24	  kcal/oz	  in	  order	  to	  help	  meet	  the	  increased	  caloric	  needs	  of	  BA	  patients14.	  	  The	  child	  refused	  to	  drink	  Pregestimil	  because	  of	  gas	  and	  discomfort	  after	  feedings,	  possibly	  related	  to	  lactose-­‐intolerance,	  so	  she	  was	  given	  Prosobee	  instead.	  Prosobee	  is	  a	  soy-­‐based,	  lactose-­‐free	  formula	  for	  infants	  with	  lactose-­‐intolerance15.	  However	  Prosobee’s	  MCT:LCT	  ratio	  is	  unknown27.	  	  As	  the	  patient	  grew	  older,	  she	  was	  supplemented	  with	  Pediasure	  Peptide	  in	  addition	  to	  her	  baby	  foods.	  Pediasure	  Peptide	  is	  a	  nutritionally	  complete,	  peptide-­‐based	  formula,	  which	  was	  created	  to	  meet	  the	  needs	  of	  children	  with	  malabsorption17.	  Its	  primary	  protein	  source	  is	  hydrolyzed	  whey17.	  Pediasure	  Peptide	  contains	  a	  high	  MCT:LCT	  ratio	  of	  60:4026.	  	  
	  
Fat-­‐Soluble	  Vitamins:	  Patients	  with	  BA	  lack	  sufficient	  amounts	  of	  bile	  in	  the	  intestine	  to	  properly	  digest	  fats	  and	  absorb	  ADEK	  vitamins.	  Therefore,	  ADEK	  deficiency	  is	  common	  in	  these	  patients	  due	  to	  chronic	  malabsorption11.	  ADEK	  vitamins	  are	  important	  for	  many	  human	  functions.	  	  Light	  stimulates	  11-­‐cis-­‐retinal,	  a	  form	  of	  vitamin	  A,	  to	  be	  converted	  to	  all-­‐trans-­‐retinal28.	  This	  reaction	  results	  in	  rhodopsin	  becoming	  opsin,	  causing	  a	  nerve	  impulse	  to	  be	  sent	  to	  the	  brain,	  initiating	  non-­‐color	  vision11,28.	  Night	  blindness	  is	  a	  common	  clinical	  presentation	  of	  vitamin	  A	  deficiency.	  	  Vitamin	  E,	  as	  alpha-­‐tocopherol,	  primarily	  functions	  as	  an	  antioxidant	  in	  the	  membrane	  of	  cells	  to	  halt	  chain	  reactions	  of	  lipid	  peroxidation11,29.	  Vitamin	  E	  deficiency	  may	  result	  in	  a	  decline	  of	  immune	  functions,	  peripheral	  neuropathy,	  ophthalmoplegia,	  and	  ataxia11,29.	  	  	  Vitamin	  K’s	  most	  vital	  role	  occurs	  in	  the	  blood	  coagulation	  cascade.	  When	  glutamate	  is	  gamma-­‐carboxylated	  it	  is	  able	  to	  form	  calcium	  bridges	  between	  blood	  platelets	  and	  vascular	  and	  endothelial	  cells,	  allowing	  the	  blood	  to	  clot30.	  In	  order	  to	  gamma-­‐carboxylate	  glutamate,	  vitamin	  K	  hydroquinone	  must	  be	  oxidized	  to	  vitamin	  K	  epoxide30.	  Therefore,	  vitamin	  K	  is	  essential	  for	  blood	  coagulation.	  Hemorrhaging,	  particularly	  from	  esophageal	  varices,	  is	  a	  common	  clinical	  symptom	  of	  vitamin	  K	  deficiency	  in	  BA	  patients11.	  	  	  Calcitriol,	  the	  active	  form	  of	  vitamin	  D,	  is	  required	  for	  the	  transcellular	  transport	  of	  calcium	  from	  the	  gut	  lumen	  into	  the	  blood,	  and	  is	  therefore	  necessary	  for	  calcium	  absorption11,31.	  Calcitriol	  also	  stimulates	  intestinal	  absorption	  of	  phosphorus,	  mobilization	  of	  phosphorus	  and	  calcium	  from	  the	  bone,	  and	  reabsorption	  of	  phosphorus	  and	  calcium	  from	  the	  kidney11,31.	  Overall,	  calcitriol	  stimulates	  an	  increase	  of	  serum	  calcium	  and	  phosphorus31.	  Vitamin	  D	  deficiency	  may	  cause	  a	  decrease	  in	  serum	  calcium,	  leading	  to	  calcium	  deficiency11.	  Therefore,	  rickets	  and	  osteoporosis	  are	  common	  clinical	  presentations	  in	  those	  with	  Vitamin	  D	  deficiencies11,31.	  Vitamin	  D	  levels	  are	  low	  in	  the	  majority	  of	  BA	  patients,	  and	  remain	  low	  even	  one	  year	  after	  a	  successful	  Kasai	  procedure32.	  The	  best	  strategy	  to	  increase	  vitamin	  D	  levels	  in	  BA	  patients	  remains	  unknown32.	  A	  recent	  study	  
indicates	  that	  vitamin	  D	  is	  better	  absorbed	  when	  it	  is	  administered	  with	  D-­‐alpha-­‐tocopherol	  polyethylene	  glycol-­‐1000	  succinate	  (TPGS),	  a	  form	  of	  vitamin	  E10.	  	  Since	  ADEK	  deficiencies	  are	  common	  in	  patients	  with	  BA,	  it	  is	  necessary	  to	  provide	  oral	  ADEK	  supplements	  to	  this	  population	  in	  order	  to	  prevent	  clinical	  problems4.	  If	  biochemical	  and/or	  clinical	  signs	  of	  ADEK	  deficiency	  persist	  when	  adequate	  oral	  supplementation	  is	  provided,	  parenteral	  ADEK	  supplementation	  is	  recommended10.	  	  	  
Oral	  Intake	  vs.	  Enteral	  Nutrition:	  Children	  with	  BA	  have	  increased	  nutritional	  needs	  and	  are	  unable	  to	  grow	  appropriately	  if	  exclusively	  breastfeeding.	  Although	  oral	  intake	  is	  encouraged	  in	  order	  to	  maintain	  psychological	  health	  and	  develop	  feeding	  skills,	  it	  is	  recommended	  that	  EN	  be	  used	  to	  supplement	  oral	  intake	  to	  achieve	  adequate	  nutrition10,19.	  	  However,	  controversy	  lies	  in	  how	  to	  administer	  the	  EN.	  Some	  researchers	  believe	  that	  oral	  intake	  with	  continuous	  infusions	  of	  EN	  will	  result	  in	  less	  regurgitation,	  and	  therefore	  better	  growth	  overall11.	  However,	  more	  recent	  studies	  found	  that	  daily	  oral	  intake	  with	  cycled	  nocturnal	  infusions	  of	  EN	  achieved	  adequate	  nutrition	  for	  infants	  with	  prolonged	  cholestasis19.	  In	  this	  case	  study,	  the	  child	  was	  fed	  formula	  orally	  and	  given	  ADEK	  supplements.	  She	  received	  no	  EN.	  
	  
Overfeeding	  BA	  Patients:	  Although	  it	  is	  important	  to	  feed	  BA	  patients	  enough	  to	  obtain	  appropriate	  growth	  and	  development,	  a	  more	  successful	  liver	  transplant	  operation,	  and	  post-­‐transplant	  success6,	  we	  must	  be	  cautious.	  A	  recent	  study	  followed	  a	  representative	  cohort	  of	  1,706	  individuals	  who	  received	  a	  liver	  transplant	  between	  the	  years	  1995	  and	  200733.	  The	  study	  shows	  that	  the	  prevalence	  of	  obesity	  in	  pediatric	  liver	  transplant	  recipients	  three	  years	  post-­‐transplant	  is	  extremely	  high	  (19.2%)33.	  The	  prevalence	  of	  obesity	  in	  2-­‐5	  year	  olds	  who	  have	  undergone	  liver	  transplantation	  is	  significantly	  higher	  when	  compared	  with	  the	  general	  population33.	  The	  most	  prominent	  predictor	  of	  obesity	  after	  liver	  transplantation	  is	  obesity	  before	  transplant33.	  Therefore,	  although	  it	  is	  important	  for	  BA	  patients	  to	  receive	  adequate	  nutrition,	  we	  must	  not	  overfeed	  in	  order	  to	  decrease	  risk	  for	  obesity	  after	  liver	  transplantation.	  	  In	  order	  to	  reach	  the	  top	  of	  the	  pediatric	  liver	  transplant	  waitlist,	  the	  patient	  must	  have	  a	  high	  PELD	  score.	  If	  the	  patient	  fails	  to	  grow	  normally/adequately,	  the	  PELD	  score	  is	  higher.	  If	  a	  BA	  patient	  is	  overfed,	  the	  higher	  weight	  will	  result	  in	  a	  lower	  PELD	  score	  and	  increased	  time	  on	  the	  pediatric	  liver	  transplant	  waitlist.	  	  Pediatric	  Liver	  Transplant	  Waitlist	  The	  PELD	  score	  accounts	  for	  laboratory	  values,	  such	  as	  albumin,	  bilirubin,	  prothrombin	  time,	  age,	  and	  growth	  failure	  based	  on	  sex,	  height,	  and	  weight	  at	  listing34.	  It	  is	  common	  for	  the	  BA	  population	  to	  have	  deceptively	  low	  PELD	  scores	  because	  of	  misinterpreted	  albumin	  levels	  and	  growth	  patterns1,6.	  Albumin	  levels	  are	  a	  better	  measurement	  of	  the	  extent	  of	  liver	  disease	  than	  nutritional	  status10.	  The	  assessment	  of	  BA	  patients’	  body	  weights	  may	  be	  misleading	  because	  of	  hepatomegaly,	  edema,	  and/or	  ascites6.	  Therefore,	  it	  is	  important	  to	  use	  accurate	  measurements	  when	  evaluating	  growth.	  Height	  is	  a	  more	  reliable	  measurement	  than	  weight	  when	  identifying	  children	  with	  chronic	  malnutrition10.	  However,	  
triceps	  skin	  fold	  (TSF)	  and	  mid-­‐upper	  arm	  circumference	  (MUAC)	  measurements	  are	  the	  most	  accurate	  indicators	  of	  body	  composition	  because	  variations	  in	  these	  measurements	  appear	  earlier	  than	  changes	  in	  height10.	  TSF	  and	  MUAC	  measure	  the	  amount	  of	  subcutaneous	  fat,	  and	  fat	  is	  the	  ideal	  parameter	  to	  measure	  nutritional	  status	  in	  children	  with	  cirrhotic	  livers	  because	  fat	  is	  the	  major	  form	  of	  stored	  energy	  in	  the	  body10.	  	  The	  number	  of	  deaths	  has	  increased	  in	  children	  waiting	  for	  an	  organ	  transplant	  who	  are	  less	  than	  12	  months	  old1.	  In	  response,	  transplant	  centers	  are	  increasingly	  appealing	  Regional	  Review	  Boards	  for	  exception	  points1.	  The	  review	  boards	  grant	  exception	  points	  on	  a	  case-­‐by-­‐case	  basis	  in	  order	  for	  the	  PELD	  score	  to	  better	  represent	  the	  severity	  of	  the	  patient’s	  disease1.	  There	  was	  a	  five-­‐fold	  increase	  in	  the	  use	  of	  PELD	  exception	  points	  from	  2002-­‐20131.	  Rates	  of	  exception	  score	  requests	  are	  particularly	  high	  in	  children	  less	  than	  twelve	  months	  of	  age	  living	  with	  BA;	  however	  those	  listed	  with	  exception	  scores	  are	  more	  likely	  to	  be	  white	  and	  privately	  insured,	  suggesting	  bias1.	  	  	  Pancreatic	  Enzymes:	  	  Lipases	  are	  enzymes	  that	  are	  excreted	  from	  the	  pancreas	  into	  the	  intestine	  to	  aid	  in	  fat	  digestion.	  These	  enzymes	  hydrolyze	  fats	  (triglycerides)	  into	  monoacylglycerol	  and	  fatty	  acids,	  which	  combine	  with	  bile	  and	  other	  byproducts	  to	  form	  a	  micelle.	  The	  micelle	  moves	  close	  to	  the	  brush	  border	  of	  the	  mucosal	  cells	  of	  the	  small	  intestine	  to	  allow	  lipids	  to	  diffuse	  into	  the	  mucosal	  cells21.	  Since	  the	  pancreas	  is	  anatomically	  adjacent	  to	  the	  hepatobiliary	  system,	  children	  with	  cholestatic	  diseases	  were	  thought	  to	  possibly	  have	  exocrine	  pancreatic	  insufficiency8.	  However,	  children	  living	  with	  BA	  were	  actually	  found	  to	  have	  elevated	  serum	  pancreatic	  enzyme	  concentrations	  when	  compared	  to	  children	  without	  jaundice,	  and	  therefore	  did	  not	  express	  exocrine	  pancreatic	  insufficiency8.	  These	  results	  are	  compatible	  with	  similar	  research	  studies8.	  	  	  
Conclusions	  	  According	  to	  the	  most	  recent	  research,	  the	  best	  nutritional	  treatment	  for	  BA	  patients	  before	  liver	  transplantation	  includes	  cycled	  EN	  nocturnal	  feeding	  with	  daily	  oral	  feeds	  using	  formula	  with	  a	  high	  MCT:LCT	  ratio10,19.	  To	  prevent	  deficiencies,	  it	  is	  strongly	  recommended	  that	  BA	  patients	  be	  provided	  with	  130-­‐150%	  of	  the	  caloric	  DRI	  for	  age,	  2.5-­‐3	  g/kg/d	  of	  protein,	  and	  ADEK	  supplements10,11,32.	  	  	  After	  liver	  transplantation,	  it	  is	  recommended	  that	  total	  parenteral	  nutrition	  be	  provided	  for	  about	  two	  days,	  until	  the	  surgical	  ileus	  resolves,	  and	  then	  advance	  the	  patient’s	  diet	  to	  EN.	  Patients	  continue	  to	  be	  at	  high	  risk	  for	  malabsorption	  after	  transplant	  surgery	  because	  of	  previous	  malnutrition10.	  Therefore,	  it	  is	  recommended	  that	  BA	  patients	  begin	  with	  an	  elemental	  formula,	  which	  is	  easier	  to	  digest,	  before	  advancing	  to	  a	  standard	  formula10.	  It	  is	  also	  suggested	  that	  vitamin	  D	  and	  calcium	  supplementation	  continue	  after	  liver	  transplantation	  to	  avoid	  metabolic	  bone	  disease10.	  It	  is	  crucial	  to	  continue	  monitoring	  the	  patient’s	  diet	  for	  about	  three	  years	  after	  liver	  transplantation	  in	  order	  to	  confirm	  that	  the	  nutrition	  being	  provided	  is	  promoting	  appropriate	  growth10.	  	  
When	  examining	  the	  growth	  of	  a	  BA	  patient,	  it	  is	  important	  to	  measure	  fat	  mass	  instead	  of	  weight.	  Body	  weight	  may	  be	  deceptively	  high	  in	  this	  population	  due	  to	  hepatomegaly	  and	  fluid	  retention.	  Therefore,	  TSF	  and	  MUAC	  are	  the	  most	  accurate	  measures	  of	  a	  BA	  patient’s	  growth.	  	  	  The	  child’s	  PELD	  score	  has	  increased	  since	  she	  was	  approved	  for	  the	  pediatric	  liver	  transplant	  waitlist	  because	  she	  was	  given	  exception	  points	  for	  frequent	  GI	  bleeding.	  Her	  current	  PELD	  score,	  at	  19	  months	  of	  age,	  is	  35.	  Her	  PELD	  score	  is	  now	  above	  the	  median	  PELD	  score	  of	  a	  child	  at	  the	  time	  of	  pediatric	  liver	  transplantation1.	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